Griffin Deborah A 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 5, 2020
Insider Transaction Report
Form 4
Griffin Deborah A
Chief Accounting Officer
Transactions
- Exercise/Conversion
Restricted Share Units
2020-03-04−4,807→ 14,424 total→ Ordinary Shares (4,807 underlying) - Exercise/Conversion
Ordinary Shares
2020-03-04+4,807→ 4,807 total - Sale
Ordinary Shares
2020-03-04$11.23/sh−4,807$53,980→ 0 total
Footnotes (4)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.0900 to $11.3800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]Restricted share units were granted on March 4, 2019, with 4,807 vesting on each of March 4, 2020, March 4, 2021 and March 4, 2022 and 4,810 vesting on March 4, 2023.